Description of Collaborative Activity: |
This Memorandum of Understanding (MOU) provides a mechanism for addressing cross-cutting issues related to drug therapy development for neurological disorders, from bench science to clinical trials and the Food and Drug Administration (FDA) approval and licensure. |